ArticleJournal for immunotherapy of cancer2019

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status.

Fotios Loupakis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.